Smad4 suppresses the progression of renal cell carcinoma via the activation of forkhead box protein H1

Liu,Yunli; Xu,Yangyang; Li,Xuedong; Chen,Zhaoyan

doi:10.3892/mmr.2014.3061

Smad4 suppresses the progression of renal cell carcinoma via the activation of forkhead box protein H1

Authors:
- Yunli Liu
- Yangyang Xu
- Xuedong Li
- Zhaoyan Chen
View Affiliations

Affiliations: Department of Urological Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Urological Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: December 8, 2014 https://doi.org/10.3892/mmr.2014.3061
Pages: 2717-2722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Smad4 has recently been identified as a tumor suppressor gene in a variety of cancers, yet the role of Smad4 in renal cell carcinoma (RCC) remained to be elusive. Therefore, the aim of the present study was to explore the function of Smad4 in RCC. The expression of Smad4 reduced the growth rate of RCC. The levels of Smad4 and forkhead box protein H1 (FOXH1) mRNA were reduced, while the levels of estrogen receptor were increased in RCC cells compared with those in human renal epithelial cells (P<0.01). Western blot analysis showed an identical trend among the three molecules. Glutathione S‑transferase pull‑down and immunoprecipitation assays proved the interaction between Smad4 and FOXH1. An immunofluorescence assay revealed that Smad4 and FOXH1 were colocalized in the nuclei of RCC cells. Smad4 interacts with Smad2 and migrates into the nucleus, where it interacts with FOXH1 to repress the protein expression of estrogen receptor. These results indicate that Smad4 acts as a tumor suppressor by activating FOXH1, and then suppressing the expression of estrogen receptor, in addition to tumor migration and invasion. Hence, Smad4 should be investigated as a potential target for the treatment for RCC.

View Figures

View References

1	Sheehan JP, Sun MH, Kondziolka D, Flickinger J and Lunsford LD: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 98:342–349. 2003. View Article : Google Scholar : PubMed/NCBI
2	Ljungberg B, Hanbury DC, Kuczyk MA, et al; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 51:1502–1510. 2007. View Article : Google Scholar : PubMed/NCBI
3	Linehan WM: The genetic basis of kidney cancer: implications for management and use of targeted therapeutic approaches. Eur Urol. 61:896–898. 2012. View Article : Google Scholar : PubMed/NCBI
4	Jacobs JF, Nierkens S, Figdor CG, de Vries IJM and Adema GJ: Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 13:e32–e42. 2012. View Article : Google Scholar : PubMed/NCBI
5	de Jesus-Gonzalez N, Robinson E, Moslehi J and Humphreys BD: Management of antiangiogenic therapy-induced hypertension. Hypertension. 60:607–615. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhu Y, Xu L, Zhang J, et al: Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
7	Kim BG, Li C, Qiao W, et al: Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature. 441:1015–1019. 2006. View Article : Google Scholar : PubMed/NCBI
8	Wang LH, Kim SH, Lee JH, et al: Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res. 13:102–110. 2007. View Article : Google Scholar : PubMed/NCBI
9	Müller N, Reinacher-Schick A, Baldus S, et al: Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells. Oncogene. 21:6049–6058. 2002. View Article : Google Scholar : PubMed/NCBI
10	Losi L, Bouzourene H and Benhattar J: Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep. 17:1095–1099. 2007.PubMed/NCBI
11	Alazzouzi H, Alhopuro P, Salovaara R, et al: SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 11:2606–2611. 2005. View Article : Google Scholar : PubMed/NCBI
12	Goto Y, Manabe N, Uchio-Yamada K, et al: Augmented cytoplasmic Smad4 induces acceleration of TGF-beta1 signaling in renal tubulointerstitial cells of hereditary nephrotic ICGN mice with chronic renal fibrosis; possible role for myofibroblastic differentiation. Cell Tissue Res. 315:209–221. 2004. View Article : Google Scholar
13	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
14	ten Dijke P and Hill CS: New insights into TGF-β-Smad signalling. Trends Biochem Sci. 29:265–273. 2004. View Article : Google Scholar : PubMed/NCBI
15	Hoodless PA, Tsukazaki T, Nishimatsu S, Attisano L, Wrana JL and Thomsen GH: Dominant-negative Smad2 mutants inhibit activin/Vg1 signaling and disrupt axis formation in Xenopus. Dev Biol. 207:364–379. 1999. View Article : Google Scholar : PubMed/NCBI
16	Attisano L and Wrana JL: Smads as transcriptional co-modulators. Curr Opin Cell Biol. 12:235–243. 2000. View Article : Google Scholar : PubMed/NCBI
17	Yum J, Jeong HM, Kim S, et al: PKA-mediated stabilization of FoxH1 negatively regulates ERalpha activity. Mol Cells. 28:67–71. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bhat HK, Hacker HJ, Bannasch P, Thompson EA and Liehr JG: Localization of estrogen receptors in interstitial cells of hamster kidney and in estradiol-induced renal tumors as evidence of the mesenchymal origin of this neoplasm. Cancer Res. 53:5447–5451. 1993.PubMed/NCBI
19	Tsui K-H, Shvarts O, Smith Rb, Figlin Ra, de Kernion J and Belldegrun A: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 163:1090–1095. 2000. View Article : Google Scholar : PubMed/NCBI
20	Wu J-W, Hu M, Chai J, et al: Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell. 8:1277–1289. 2001. View Article : Google Scholar
21	Shi Y, Hata A, Lo RS, Massagué J and Pavletich NP: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 388:87–93. 1997. View Article : Google Scholar : PubMed/NCBI
22	Itoh F, Asao H, Sugamura K, Heldin C-H, ten Dijke P and Itoh S: Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 20:4132–4142. 2001. View Article : Google Scholar : PubMed/NCBI
23	Ju W, Ogawa A, Heyer J, et al: Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol Cell Biol. 26:654–667. 2006. View Article : Google Scholar :
24	Yao Z, Fenoglio S, Gao DC, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
25	Yamamoto M, Meno C, Sakai Y, et al: The transcription factor FoxH1 (FAST) mediates Nodal signaling during anterior-posterior patterning and node formation in the mouse. Genes Dev. 15:1242–1256. 2001. View Article : Google Scholar : PubMed/NCBI
26	Chen G, Nomura M, Morinaga H, et al: Modulation of androgen receptor transactivation by FoxH1 a newly identified androgen receptor corepressor. J Biol Chem. 280:36355–36363. 2005. View Article : Google Scholar : PubMed/NCBI
27	Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI